Abstract: This disclosure provides a consolidated electric motor stator lamination for multiple enclosure types such that a single stator assembly can be used for different classifications of an electric motor. Each layer of the stator lamination includes external features that, when combined with the external features of the other layers in the lamination, can be adapted to conform the electric motor to one of a plurality of enclosure types. The external features include retaining features for one or more covers, fins, and a profile configured to accept cooling tubes. In various embodiments, a single consolidated stator lamination assembly can be adapted to provide a motor having at least two of an open-drip proof (ODP), a totally enclosed fan cooled (TEFC), or a totally enclosed water cooled (TEWC) enclosure classification.

Abstract: The present disclosure is directed to compositions comprising modified interferon-?2 polypeptides having interferon-?2 activity and reduced immunogenicity. In aspects, said modified interferon-?2 polypeptides are hyperglycosylated, such as by addition of a GM-CSF-derived peptide sequence with multiple O-glycosylation sites. Furthermore, the present disclosure provides compositions comprising a nucleic acid molecule encoding said modified interferon-?2. The present disclosure also provides compositions comprising a recombinant protein expression cell line comprising said nucleic acid molecule encoding said modified interferon-?2; wherein said recombinant protein expression cell comprises a plasmid or vector containing said nucleic acid molecule. Also disclosed are pharmaceutical compositions comprising a modified interferon-?2 having interferon-?2 activity with reduced immunogenicity, as well as methods of use of said pharmaceutical formulations for treatment of medical conditions in a subject.

Abstract: The invention relates to improved strategies, compositions, and methods for producing neoplasia vaccines and for their use in methods of treating cancer in a patient. In aspects, a method of treating cancer comprises: (a) administering an effective amount of one or more of the instantly-disclosed peptides or polypeptides comprising one or more identified shared neo-epitopes (including peptides or polypeptide comprising one or more peptides or polypeptides from Table A, B, and/or C and/or fragments and variants thereof); and subsequently (b) administering an effective amount of one or more of the instantly-disclosed subject-specific peptides or polypeptides comprising one or more identified subject-specific neo-epitopes. The peptides or polypeptides administered in step (a) and in step (b) are designed to exclude neo-epitopes that are known or determined (e.g.

Abstract: The present invention relates to improved strategies, compositions, and methods for producing shared neoplasia vaccines, including “off the shelf” pre-furnished shared neo-epitope warehouses, which can be used to enable the rapid production of bladder cancer neoantigen-based vaccines. The present invention relates to identified and designed shared neo-epitopes based on non-synonymous mutations that are present in at least 1% of subjects having bladder cancer. The strategies, compositions, and methods include the identification of neo-epitopes that are known or determined (e.g. predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) and exclusion of such identified neo-epitopes that are known or determined (e.g.

Abstract: The invention provides improved strategies, prognostic indicators, compositions, and methods for producing personalized neoplasia vaccines. More particularly, embodiments of the present disclosure relate to the identification of neoplasia-specific neo-epitopes to predict survival and to identify and design subject-specific neo-epitopes, further assessing the identified neo-epitopes encoded by said mutations to identify neo-epitopes that are known or determined, or predicted to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells), and excluding such neo-epitopes that are known, determined, or predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) from the subject-specific neo-epitopes that are to be used in personalized neoplasia vaccines.

Abstract: The invention relates to improved strategies, compositions, and methods for producing neoplasia vaccines and for their use in methods of treating cancer in a patient. In aspects, a method of treating cancer comprises: (a) administering an effective amount of one or more of the instantly-disclosed peptides or polypeptides comprising one or more identified shared neo-epitopes (including peptides or polypeptide comprising one or more peptides or polypeptides from Table A, B, and/or C and/or fragments and variants thereof); and subsequently (b) administering an effective amount of one or more of the instantly-disclosed subject-specific peptides or polypeptides comprising one or more identified subject-specific neo-epitopes. The peptides or polypeptides administered in step (a) and in step (b) are designed to exclude neo-epitopes that are known or determined (e.g.

Abstract: The present invention relates to improved strategies, compositions, and methods for producing shared neoplasia vaccines, including “off the shelf” pre-furnished shared neo-epitope warehouses, which can be used to enable the rapid production of bladder cancer neoantigen-based vaccines. The present invention relates to identified and designed shared neo-epitopes based on non-synonymous mutations that are present in at least 1% of subjects having bladder cancer. The strategies, compositions, and methods include the identification of neo-epitopes that are known or determined (e.g. predicted) to engage regulatory T cells and/or other detrimental T cells (including T cells with potential host cross-reactivity and/or anergic T cells) and exclusion of such identified neo-epitopes that are known or determined (e.g.

Abstract: The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Abstract: The present technology is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Abstract: The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Abstract: The present technology is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Abstract: The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Abstract: The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.

Abstract: The invention relates to washpipes for use in drilling operations such as drilling for oil and gas, and more particularly to an auto lubricating washpipe and liner system and method.

Abstract: The invention relates to washpipes for use in drilling operations such as drilling for oil and gas, and more particularly to an auto lubricating washpipe and liner system and method.

Abstract: A method and apparatus providing a modular security cage configured to be disposed over a base surface to secure and maintain equipment within the security cage. The modular security cage includes multiple frame panels with multiple coupling tabs extending from each of the multiple frame panels. Each of the frame panels are operable to be modularly coupled to each other to form at least a four-sided cubic shaped cage. Each of the coupling tabs are configured to extend internally within the cubic shaped cage and are operable to be secured to another tab extending from an adjacent one of the frame panels to removably couple each frame panel together to form the cubic shaped cage. In another embodiment, the cage can include at least one pivot shoe configured to suspend the cage above the base surface to allow the cage to pivot upward to provide accessibility therein.

Abstract: A motorized trackboard has a rear-mounted engine (4) which transmits rotary motion centrally to a rear-driven track (2) at each side of a trackboard platform (1). Different types of track, different types of gear means, different sizes and different human-factor accommodations are employed for different use-conditions. For some use-conditions, a rear track-drive wheel (3) is large and sturdy to support all weight on the trackboard for positioning weight on the rear to raise the front end for turning. A front track-support wheel (7) can be positioned higher than the axis of the rear drive wheel to provide a climbing incline (15). The front track-support wheel can be spring-tensioned in a forward direction to prevent track slack. It is an all-terrain vehicle that can be made small and light enough for child use or large enough for a seat for heavy use.

Abstract: A screen enclosure device comprising a first frame member having an interior face and a second frame member having an interior face wherein the first and second frame members are configured to join at their interior faces to form a single frame structure. Serrated contacting structure including a plurality of rows of teeth extends substantially along and is interposed in contacting relationship between the substantial full perimeter of the opposing faces of these first and second frame members. Screen material is drawn tightly across the opening of the frame and is retained in this tight configuration by forces supplied by the serrated contacting structure in its sandwiched configuration between the opposing faces of the first and second frame members.

Abstract: An axially compact rotational sensor adaptable to a drive axle for determining the rotational speed of the differential case which is the average speed of the wheels associated therewith. In a second embodiment dual rotational sensors are incorporated in the drive axle for determining the rotational speed of the differential and one axle shaft permitting calculation of the speed of both axle shafts.

Abstract: A storm door comprising a frame assembly which includes tubular metal frame members, each of the frame members having a uniform rectangular cross-sectional shape and being formed into a continuous unibody frame. The frame being rectangular in shape and including at least one opening therein. The storm door also including window and/or kick plate assemblies which include a flange member which allows the assembly to be easily inserted into the opening in the frame and attached thereto.